Precision oncology
beyond biomarkers
A significant number of highly lethal cancers remain incurable despite modern, biomarker-based precision oncology. We are convinced it is the lack of fully understanding tumor biology on a molecular basis that currently prevents development and regulatory approval of successful therapies. Tumors in this category can not be defined by single biomarkers. Instead, we must determine the patient-specific bio-signature - a complex multi-dimensional pattern of multi-omics and clinical data far beyond single biomarkers.
treatlink will start its work focusing on Glioblastoma (GBM), a primary malignant brain tumor. Once a solution has been established, the approach will be transferred to other highly lethal cancers.
Glioblastoma (GBM), a WHO Grade 4 malignant brain tumor, is considered one of the deadliest cancers there is. Almost all patients develop a relapse and therapy resistance over time.
Despite intensive research the median survival time is around 15 months with less than 6% of patients being alive after 3 years.
Over the past 25 years, around 350 entities and therapy concepts for Glioblastoma have been tested globally in around 1,000 clinical trials. Less than 1% were approved, billions of Euros were invested without the expected return.
treatlink will generate a unique and proprietary data-set for Glioblastoma by integrating results of novel multi-omics assays and clinical data. The data-set will be used for training of a super performant AI-model.
Model based stratification of patient groups will be applied to significantly increase the success rate of clinical trials. Beyond, the model will substantially improve the development of new potent (combination) therapies.